Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Alzheimer's Disease

    Current Location

    Search
    Alzheimer's Disease
    Show Map
    Map View
    Your Location
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      99 Alzheimer's Disease Trials Near You

      Power is an online platform that helps thousands of Alzheimer's Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Donanemab for Early Alzheimer's Disease

      Columbus, Ohio
      This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:60 - 85

      Key Eligibility Criteria

      Disqualifiers:MRI/PET Contraindication, Others
      Must Not Be Taking:Immunoglobulin G Therapy

      1736 Participants Needed

      Screening for Alzheimer's Disease Studies

      Columbus, Ohio
      This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Neurological Conditions, CNS Trauma, Others

      13000 Participants Needed

      KarXT + KarX-EC for Alzheimer's Disease

      Columbus, Ohio
      The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:60 - 85

      Key Eligibility Criteria

      Disqualifiers:Hepatic Impairment, Major Depression, Schizophrenia, Others
      Must Be Taking:Acetyl Choline Esterase Inhibitors, Memantine

      586 Participants Needed

      KarXT for Psychosis in Alzheimer's Disease

      Columbus, Ohio
      The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Bipolar, Major Depression, Others

      406 Participants Needed

      KarXT for Alzheimer's-Related Psychosis

      Columbus, Ohio
      This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027, CN012-0056 or CN012-0034. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study, 14-week CN012-0056 or 14 week CN012-0034 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT and KarXT + KarX-EC in subjects with psychosis associated with Alzheimer's Disease.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Severe Medical Conditions, Others

      800 Participants Needed

      ONO-2020 for Alzheimer's Disease

      Columbus, Ohio
      This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:55 - 85

      Key Eligibility Criteria

      Disqualifiers:Stroke, Schizophrenia, HIV, Others
      Must Be Taking:Acetylcholinesterase Inhibitors, Memantine

      240 Participants Needed

      CT1812 for Early Alzheimer's Disease

      Columbus, Ohio
      This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:50 - 85

      Key Eligibility Criteria

      Disqualifiers:Other Dementias, Neurodegenerative Conditions, Hepatitis, Others

      540 Participants Needed

      Benfotiamine for Alzheimer's Disease

      Columbus, Ohio
      The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:50 - 89

      Key Eligibility Criteria

      Disqualifiers:Neurological Disorders, Diabetes, Cancer, Others
      Must Be Taking:Acetylcholinesterase Inhibitors, Memantine

      406 Participants Needed

      Bepranemab for Alzheimer's Disease

      Columbus, Ohio
      This trial is testing bepranemab, a new medication, to see if it can help people with early-stage Alzheimer's disease. The study focuses on individuals who are just starting to show symptoms or have mild symptoms. Bepranemab works by removing harmful proteins from the brain that are linked to Alzheimer's.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:50 - 80

      Key Eligibility Criteria

      Disqualifiers:Alcohol/drug Abuse, Experimental Therapy, Others
      Must Not Be Taking:Atypical Antipsychotics, Opiates, Benzodiazepines, Others

      466 Participants Needed

      Sensory Stimulation for Alzheimer's Disease

      Columbus, Ohio
      This trial is testing a device that uses light and sound to help patients with mild to moderate Alzheimer's disease. The goal is to see if this sensory stimulation can slow down the progression of the disease by improving brain function. This therapy has shown potential for application in the treatment of Alzheimer's disease.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Seizure Disorder, Schizophrenia, Heart Disease, Others
      Must Be Taking:Acetylcholinesterase Inhibitors

      670 Participants Needed

      Sensory Stimulation for Alzheimer's Disease

      Columbus, Ohio
      This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study. Participants who complete the Hope Study (CA-0011) will be eligible to consent for screening to enroll in the OLE Hope Study (CA-0015). All participants will be treated with an Active Sensory Stimulation System (GS120) for 60 minutes daily for up to 12 months. There will be no Sham treatment group or randomization involved in this study.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Age:50 - 92

      Key Eligibility Criteria

      Disqualifiers:Insufficient Adherence, Continuous Care, Others
      Must Not Be Taking:Immunomodulators, Memantine, Nootropics

      402 Participants Needed

      ExAblate BBB Disruption for Alzheimer's Disease

      Columbus, Ohio
      This trial is testing a device that uses ultrasound waves to temporarily open the brain's protective barrier in patients with Alzheimer's Disease. The goal is to see if this can help medications reach the brain better. Focused ultrasound with microbubbles has been studied recently and shows promise for opening the brain's protective barrier in Alzheimer's disease treatment.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:50 - 85

      Key Eligibility Criteria

      Disqualifiers:Cardiac Disease, Depression, Seizure, Others
      Must Be Taking:Alzheimer's Medications

      150 Participants Needed

      Long-Term Safety of Simufilam for Alzheimer's Disease

      Columbus, Ohio
      The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:51 - 89

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      1081 Participants Needed

      Simufilam for Alzheimer's Disease

      Columbus, Ohio
      This trial involves patients with mild-to-moderate Alzheimer's disease taking simufilam regularly. It aims to see if the medication is safe and effective over time. Simufilam works by targeting proteins in the brain that are associated with Alzheimer's.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      90 Participants Needed

      Computerized Anxiety Treatment for Mild Alzheimer's Disease

      Columbus, Ohio
      The goal of this clinical trial is to test the effectiveness of a computerized anxiety sensitivity treatment (CAST) compared to a health education control (HEC) in older adults with mild cognitive impairment (MCI) or mild Alzheimer's Disease and related dementias (ADRD) and their care partners. The main questions it aims to answer are: 1. Efficacy of CAST in reducing anxiety and related symptoms among those with MCI/mild ADRD 2. Efficacy of CAST in reducing care partner burden among care partners of people living with MCI/mild ADRD 3. Explore treatment mechanisms using a multi-modal assessment battery of anxiety sensitivity and anxiety Participants will complete six in-person visits including a baseline assessment, two intervention sessions, and three follow-up assessments at 1, 3, and 6-months posttreatment. Participants will also complete three weeks of ecological momentary assessments (EMAs) for one week prior to intervention, one week between intervention sessions, and one week after intervention. If there is a comparison group: Researchers will compare CAST to HEC to see if CAST reduces anxiety and related symptoms in older adults with MCI/mild ADRD and care partner burden to a greater degree than HEC.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:60+

      Key Eligibility Criteria

      Disqualifiers:Severe Mental Illness, Others

      388 Participants Needed

      Smart Healthcare Technology for Alzheimer's Caregiver Support

      Columbus, Ohio
      The purpose of this project is to develop a monitoring, modeling, and interactive recommendation solution (for caregivers) for in-home dementia patient care that focuses on caregiver-patient relationships. This includes monitoring for mood and stress and analyzing the significance of monitoring those attributes to dementia patient care and subsequent behavior dynamics between the patient and caregiver. In addition, novel and adaptive behavioral suggestions at the right moments aims at helping improve familial interactions related to caregiving, which over time should ameliorate the stressful effects of the patient's illness and reduce strain on caregivers. The technical solution consists of a core set of statistical learning based techniques for automated generation of specialized modules required by in-home dementia patient care. There are three main technical components in the solution. The first obtains textual content and prosody from voice and uses advanced machine learning techniques to create classification models. This approach not only monitors patients' behavior, but also caregivers', and infers the underlying dynamics of their interactions, such as changes in mood and stress. The second is the automated creation of classifiers and inference modules tailored to the particular patients and dementia conditions (such as different stages of dementia). The third is an adaptive recommendation system that closes the loop of an in-home behavior monitoring system.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:21 - 99

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      100 Participants Needed

      AAV2-BDNF Gene Therapy for Alzheimer's Disease

      Columbus, Ohio
      This trial tests a new gene therapy that uses a virus to deliver a protective protein called BDNF into the brains of people with early Alzheimer's Disease and Mild Cognitive Impairment. The goal is to help brain cells survive, function better, and form new connections. The therapy aims to slow or prevent further brain cell loss. Brain-derived neurotrophic factor (BDNF) has been explored for its potential to support neuron survival and function in neurodegenerative diseases.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:50 - 80

      Key Eligibility Criteria

      Disqualifiers:Neurological Disease, Major Depression, Cancer, Others
      Must Be Taking:Anti-cholinesterases, Memantine

      12 Participants Needed

      JNJ-63733657 for Alzheimer's Disease

      Columbus, Ohio
      This trial is testing a new drug called JNJ-63733657 to see if it can help slow down the worsening of symptoms in patients with Alzheimer's disease. The goal is to see if the drug can help maintain brain function and daily living skills better.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:55 - 80

      Key Eligibility Criteria

      Disqualifiers:MCI, Parkinson's, Alcohol Abuse, Others
      Must Be Taking:AD Treatments

      523 Participants Needed

      Nicotine Patch for Mild Cognitive Impairment

      Columbus, Ohio
      The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function. The study will enroll 380 participants for a 2 year period. Participants will be randomized (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day, or placebo skin patch.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Tobacco Use, Neurologic Disease, Major Depression, Others
      Must Be Taking:Memantine, Cholinesterase Inhibitors

      380 Participants Needed

      Escitalopram for Agitation in Alzheimer's Disease

      Columbus, Ohio
      The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      187 Participants Needed

      Why Other Patients Applied

      "I watched my mother die from Parkinson’s. At the time of her death, she weighed 85 pounds and could not move any muscles voluntarily except her eyelids. I would like to participate in a trial to help find a better treatment for PD than what is currently available. It is a devastating illness. It breaks my heart that other families will have to go through this."

      WU
      Healthy Volunteer PatientAge: 76

      "I have a very strong family history of Alzheimer’s, with my maternal grandmother, mother, uncle, and sister having the disease. My APOE status is 2/4. My memory is going, although 6 months ago I tested decently on some cognitive tests. I'd like to help myself by getting ahead of my condition and help others in a similar situation by participating in medical research."

      EK
      Mild Cognitive Impairment PatientAge: 72

      "I watched my mother suffer through years of Alzheimer's Disease and I want to help advance the science for treating AD. I don't want anyone else to have go through what our family went through."

      OF
      Alzheimer's Disease PatientAge: 65

      "I'm so used to losing things, forgetting things, making up to acronyms to remember things only to remember the acromym but not what the letters stand for... I enter a new room to look for an item, only to forget what I was looking for. I've discussed the existing treatments with my neurologist and she's on board with my joining a clinical trial."

      AH
      Dementia PatientAge: 64

      "I have been on standard Alzheimer's medication for a few years but know this treatment only works to delay my cognitive deterioration, not improve it. I've been doing research, which brought me here, to consider some of the latest research drugs. While I know that there's no guarantee that a clinical trial improves my condition, I'd like to give one a try and help further the research for all."

      VL
      Alzheimer's PatientAge: 71
      Match to a Alzheimer's Disease Trial

      AVP-786 for Agitation in Alzheimer's Disease

      Columbus, Ohio
      This trial tests a combination of two drugs taken by mouth to help calm severe agitation in people with Alzheimer's disease by balancing brain chemicals.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Non-Alzheimer's Dementia, Unstable Systemic Diseases, Myasthenia Gravis, Others

      183 Participants Needed

      AVP-786 for Agitation in Alzheimer's Disease

      Columbus, Ohio
      This trial is testing a medication called AVP-786 on individuals who have taken part in previous studies. The goal is to see if this medication can help with their conditions over time.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      1197 Participants Needed

      Buntanetap for Alzheimer's Disease

      Beavercreek, Ohio
      The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13? * Does buntanetap/Posiphen improve function as measured by ADCS-iADL? * What medical issues do participants have, if any, when taking buntanetap/Posiphen? Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease. Participants will: * Take buntanetap/Posiphen or a placebo every day for 18 months * Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18 * Complete pre- and post-clinic visit phone calls
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 85

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Bipolar, Major Depression, Others
      Must Be Taking:Cholinesterase Inhibitors, Memantine

      760 Participants Needed

      AR1001 for Alzheimer's Disease

      Dayton, Ohio
      This trial tests AR1001, a medicine for early Alzheimer's Disease. It focuses on people in the early stages of Alzheimer's, aiming to improve their condition through multiple mechanisms.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Delirium, Schizophrenia, Cancer, Others
      Must Be Taking:Cholinesterase Inhibitors, Memantine

      1535 Participants Needed

      Donanemab for Alzheimer's Disease

      Dayton, Ohio
      This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:65 - 80

      Key Eligibility Criteria

      Disqualifiers:Mild Cognitive Impairment, Dementia, Cancer, Others
      Must Not Be Taking:Cognitive Enhancers

      2996 Participants Needed

      KarXT for Alzheimer's-Related Psychosis

      Dayton, Ohio
      This trial is testing KarXT, a medication for adults aged 55-90 with Alzheimer's Disease and severe psychosis. The goal is to see if KarXT can reduce symptoms like hallucinations and delusions by balancing brain chemicals.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Major Depression, Others

      400 Participants Needed

      [18F]PI-2620 PET Imaging for Alzheimer's Disease

      Centerville, Ohio
      This trial tests a brain scan that uses a special substance to detect harmful proteins in people with Alzheimer's disease.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Aggressive Treatment, Brain Lesions, Others
      Must Not Be Taking:Amyloid, Tau Therapies

      200 Participants Needed

      Remternetug for Alzheimer's Disease

      Dayton, Ohio
      This trial tests remternetug, a drug given by injection or IV, in people with early Alzheimer's disease. It aims to find out if the drug is safe and can help improve symptoms or slow down the disease.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:60 - 85

      Key Eligibility Criteria

      Disqualifiers:Unstable Illnesses, Cancer, Psychiatric Diagnosis, Others
      Must Not Be Taking:Anti-amyloid Immunotherapy

      1667 Participants Needed

      Semaglutide for Early Alzheimer's Disease

      Centerville, Ohio
      This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:55 - 85

      Key Eligibility Criteria

      Disqualifiers:Parkinson's, Schizophrenia, Bipolar, Others
      Must Be Taking:Alzheimer's Treatments

      1840 Participants Needed

      Xanomeline + Trospium for Agitation in Alzheimer's Disease

      Centerville, Ohio
      The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Schizoaffective, Others
      Must Not Be Taking:MAO Inhibitors, Anticonvulsants, Mood Stabilizers, Tricyclics

      352 Participants Needed

      1234

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      22 Alzheimer's Disease Trials near Tulsa, OK

      32 Alzheimer's Disease Trials near Syracuse, NY

      74 Alzheimer's Disease Trials near Ventura, CA

      Top Alzheimer's Disease Clinical Trials near Glendale, AZ

      Top Alzheimer's Disease Clinical Trials near Akron, OH

      40 Alzheimer's Disease Trials near Cleveland, OH

      43 Alzheimer's Disease Trials near Austin, TX

      48 Alzheimer's Disease Trials near Philadelphia, PA

      Top Lyme Disease Clinical Trials

      Top Huntington's Disease Clinical Trials

      Top Peripheral Arterial Disease Clinical Trials

      Top Degenerative Disc Disease Clinical Trials

      By Trial

      ABBV-916 for Early Alzheimer's Disease

      Risk Disclosure Impact for Alzheimer's Disease

      Ketogenic Diet vs Low-Fat Diet for Alzheimer's Disease

      Brain Safe App for Alzheimer's Disease

      Capillaroscopy for Connective Tissue Disease

      Pharmacist Intervention for Cardiovascular Disease Prevention

      GM-CSF for Peripheral Arterial Disease

      tDCS for Huntington's Disease

      Prodisc C SK & Vivo vs. Mobi-C for Cervical Disc Disease

      Crizanlizumab for Sickle Cell Disease

      Migalastat for Fabry Disease

      Rilzabrutinib for Graves' Disease

      Related Searches

      Top Esophageal-cancer Clinical Trials

      Top Clinical Trials near Denver, CO

      BMS-986258 + Nivolumab for Cancer

      Cabergoline for Inhibition of Lactation

      VLX-1005 for Heparin Induced Thrombocytopenia

      TMB-365 + TMB-380 for HIV

      Prolonged Exposure Therapy for PTSD

      Artery Embolization for Knee Pain

      Galunisertib + Chemotherapy for Rectal Cancer

      ROSE Program for Preventing Postpartum Depression

      Faith in Action! Church-based Navigation for Breast Cancer Screening

      ION363 for ALS

      Frequently Asked Questions

      How much do Alzheimer's Disease clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Alzheimer's Disease clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Alzheimer's Disease trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Alzheimer's Disease is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Alzheimer's Disease medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Alzheimer's Disease clinical trials?

      Most recently, we added Prehabilitation Interventions for Surgery Patients, KarXT + KarX-EC for Alzheimer's Disease and Health App Recommendation Tool for Alzheimer's Disease to the Power online platform.